GYRE THERAPEUTICS, INC. (GYRE) - Dilution Analysis

10-Q filing | 91.3M shares outstanding

10-K filing | 103.2M shares outstanding

10-Q filing | 90.9M shares outstanding

10-Q filing | 102.7M shares outstanding

8-K filing: Gyre Therapeutics, Inc. entered into an underwriting agreement to issue and sell 2,222,222 shares of common stock at $9.00 per share in a public offering.

10-Q filing | 86.4M shares outstanding

10-K filing | 85.1M shares outstanding

S-3 filing: The filing is an S-3 shelf registration for the potential issuance of up to $150,000,000 in aggregate principal amount of common stock, preferred stock and/or debt securities.

10-Q filing | 85.6M shares outstanding

10-Q filing | 85.5M shares outstanding

RW filing: This is a request to withdraw the registration statement on Form S-3, File No. 333-279822, filed on May 30, 2024, for the registration of up to $150,000,000 in aggregate principal amount of the Registrant's common stock, preferred stock, debt securities, warrants and/or units.

RW filing: Gyre Therapeutics, Inc. requests to withdraw the registration statement on Form S-3 filed on May 30, 2024, related to the resale of common stock by a selling stockholder due to the company's decision not to register the securities for resale.

S-3 filing: The company may issue up to $150,000,000 in aggregate principal amount of common stock, preferred stock, and/or debt securities.

S-3 filing: This S-3 filing relates to the potential resale from time to time by the Selling Stockholder of up to 1,081,332 shares of common stock of Gyre Therapeutics, Inc.

10-Q filing | 83.3M shares outstanding

10-K filing | 85.4M shares outstanding

RW filing: This is a request to withdraw registration statement on Form S-3. The Registration Statement was filed with the Commission in connection with the resale by a selling stockholder of shares of the Registrant's common stock

S-3 filing: This S-3 filing relates to the potential resale of up to 1,081,333 shares of common stock by the Selling Stockholder, consisting of shares issuable upon the conversion of Convertible Preferred Stock and the exercise of warrants.

8-K filing | Stock split 1-for-15 | Outstanding: 37,976,764 → 569,651,460 | Transactions: Sale 811 Preferred stock $5.0M to GNI USA; Issuance 811 Warrant to GNI USA; Issuance 341652 Option; Issuance 68760 Option; Issuance 341652 Option; Issuance 34380 Option; Issuance 34380 Option; Issuance 1866 Option; Issuance 45923340 Common stock to GNI USA; Issuance 17664779 Common stock to GNI USA; Issuance 10463627 Common stock to Minority Holders | Proceeds: $5.0M

10-Q filing | 38.0M shares outstanding

S-3/A filing: This S-3/A filing relates to the potential resale of up to 1,240,442,745 shares of common stock by the selling stockholders, including shares issuable upon conversion of preferred stock and shares to be issued pursuant to a Business Combination Agreement.

S-3/A filing: This S-3/A filing relates to the potential resale from time to time by the Selling Stockholders of up to 1,240,442,745 shares of common stock of Catalyst Biosciences, Inc.

10-Q filing | 37.8M shares outstanding

S-3 filing: The filing is an S-3 registration statement relating to the potential resale from time to time by the Selling Stockholders of up to 1,240,442,745 shares of common stock.

10-Q filing | 37.8M shares outstanding

10-K filing | 37.8M shares outstanding

8-K filing: Catalyst Biosciences acquired F351 Assets from GNI Group Ltd. and GNI Hong Kong Limited, issuing 6,266,521 shares of common stock and 12,340 shares of Series X Convertible Preferred Stock. ($70.0M proceeds)

10-Q filing | 31.5M shares outstanding

10-Q filing | 31.5M shares outstanding

10-Q filing | 31.5M shares outstanding

10-K filing | 31.5M shares outstanding

10-Q filing | 31.4M shares outstanding

10-Q filing | 31.4M shares outstanding

10-Q filing | 31.3M shares outstanding

10-K filing | 31.3M shares outstanding

S-3 filing: The filing is an S-3 form for a mixed shelf offering including common stock, preferred stock, and debt securities with a total proposed amount of $150,000,000.

10-Q filing | 22.1M shares outstanding

10-Q filing | 22.1M shares outstanding

10-Q filing | 17.4M shares outstanding

10-K filing | 12.1M shares outstanding